Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Merck CEO Rob Davis dubs Keytruda market exclusivity loss as 'more of a hill than a cliff' Meanwhile, in the U.S., the company’s pneumococcal conjugate vaccine Capvaxive recently scored a key ...

According to the company, sales growth was primarily due to increased usage of KEYTRUDA globally, contributions from new launches, including WINREVAIR and CAPVAXIVE, and strong growth in Merck’s ...

Davis, chairman and chief executive officer, Merck. "Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning Merck with a ...

The company launched new products like WINREVAIR and CAPVAXIVE, which are performing well and have significant commercial potential. Merck & Co Inc (NYSE:MRK) has a diversified pipeline with more ...

And Capvaxive, a vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and lung infection, was approved in the U.S. in June. Merck's ...

Davis, chairman and chief executive officer, Merck. "Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning Merck with a more ...

Merck reported third-quarter revenue and adjusted ... to treat a progressive and life-threatening lung condition. And Capvaxive, a vaccine designed to protect adults from a bacteria known ...

(1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue ...